FY2029 Earnings Estimate for Geron Issued By HC Wainwright

Geron Co. (NASDAQ:GERN) – Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Geron in a report released on Wednesday, February 26th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will earn $0.60 per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million.

Several other equities analysts have also issued reports on the company. Needham & Company LLC reduced their price target on Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday. Barclays restated an “overweight” rating and set a $4.00 price target (down from $9.00) on shares of Geron in a research report on Thursday. Scotiabank reduced their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a research report on Thursday. Stifel Nicolaus reduced their price target on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, B. Riley lowered Geron from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $3.50 to $2.00 in a research report on Thursday. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Price Performance

GERN opened at $1.76 on Friday. The stock’s 50 day simple moving average is $2.97 and its 200 day simple moving average is $3.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron has a 1 year low of $1.46 and a 1 year high of $5.34. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -5.50 and a beta of 0.53.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in shares of Geron in the 4th quarter valued at approximately $28,000. Integrated Wealth Concepts LLC purchased a new position in shares of Geron in the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new position in shares of Geron in the 4th quarter valued at approximately $45,000. Readystate Asset Management LP purchased a new position in shares of Geron in the 3rd quarter valued at approximately $58,000. Finally, Rovin Capital UT ADV purchased a new position in shares of Geron in the 3rd quarter valued at approximately $62,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.